CME Presentations
VHL and RCC
Presentations
Promising Data and Novel Therapies for Hereditary RCC: Highlight on VHL-Associated RCC
Speakers: Brian Rini, MD, Chief of Clinical Trials, Ingram Professor of MedicineEric Jonasch, MD, Professor of Genitourinary Medical Oncology Graduate School of Biomedical Sciences Duration: 60 minutes
Presented on: October 29, 2021
What’s New in the Treatment Approach for Untreated and Relapsed/Refractory Advanced RCC
Speakers: Brian Rini, MD, Chief of Clinical Trials, Ingram Professor of MedicineEric Jonasch, MD, Professor of Genitourinary Medical Oncology Graduate School of Biomedical Sciences Duration: 60 minutes
Presented on: October 29, 2021
Speakers
Brian Rini, MD
Brian Rini, MD
Chief of Clinical Trials, Ingram Professor of Medicine
Brian I. Rini, MD, FASCO, is professor of medicine and chief of clinical trials for the Vanderbilt Ingram Cancer Center (VICC) at Vanderbilt University in Nashville, Tennessee. His primary research has been in renal cell carcinoma, with special focus on antiangiogenic therapy and immunotherapy. Dr Rini’s research has been published in peer-reviewed journals, including the New England Journal of Medicine, Journal of the National Cancer Institute, Journal of Clinical Oncology, and Lancet. Certified in Medical Oncology by the American Board of Internal Medicine, he is active in numerous professional organizations, such as ASCO and the Society for Immunotherapy of Cancer (SITC). Dr Rini earned his medical degree at the Ohio State University College of Medicine in Columbus.Eric Jonasch, MD
Eric Jonasch, MD
Professor of Genitourinary Medical Oncology Graduate School of Biomedical Sciences
CME Information